American College of Clinical Pharmacy
      Search      Cart
         

SCHEDULE

Pulmonary PRN Focus Session — Hypertension That Takes Your Breath Away: Insights for Pulmonary Arterial Hypertension Management

Monday, October 14, 2024 from 1:45 PM to 3:15 PM MST at Convention Center North Building / North Ballroom 120D

Available for 1.50 hours of CPE credit
Activity Number: 0217-0000-24-136-L01-P
Activity Type: A Knowledge-Based Activity

Pulmonary arterial hypertension is a subset of the group of diseases known as pulmonary hypertension (PH), which can be a consequence of other diseases or manifest idiopathically. The recent rapid evolution of diagnostic techniques and pharmacotherapies have resulted in renewed interest in PH. Treatment of the disease can be complex and is an opportune area for pharmacist involvement. As diagnostics have improved over the years, the prevalence of this disease is becoming more common place. Accordingly, clinical pharmacists need to be comfortable with the available therapies and factors that influence the quality of care provided to persons with pulmonary hypertension. Treatment selection can be a complex process and is often dependent on the etiology of the disease. Factors considered for treatment selection include the patient comorbidities, access to proper care, the ability of care providers to navigate risk evaluation and mitigation systems, and the affordability of therapies to patients. By the end of this program, attendees will be more familiar with the etiologies, diagnosis, and treatment of pulmonary arterial hypertension. Post program, learners will be better equipped to help their patients to navigate this disease and the complexity of care it involves.

Learning Objectives

1. Describe diagnosis and classification of Pulmonary Artery Hypertension through WHO groups.

2. Recognize underlying pathophysiologies of pulmonary hypertension.

3. Discuss pulmonary arterial hypertension risk stratification utilizing multi-parameter assessment tools.

4. Summarize updates in pharmacotherapy for pulmonary arterial hypertension.

5. Summarize evidence for advances in pharmacotherapy for pulmonary hypertension from interstitial lung disease.

Jeffrey Gonzales, Pharm.D., MS, BCPS, PDE-C, CDCES
Moderator:Jeffrey Gonzales, Pharm.D., MS, BCPS, PDE-C, CDCES

Clinical Pharmacy Specialist, Transitions of Care. St. Mary Medical Center, Langhorne PA.

  View Biography

Getting to the Heart of the Matter: Diagnosis and Stratification in Pulmonary Hypertension

1:45 PM to 2:30 PM
Zach R. Smith, Pharm.D., FCCP, BCCCP, BCPS
Speaker:Zach R. Smith, Pharm.D., FCCP, BCCCP, BCPS
Clinical Pharmacy Specialist, Critical Care;
PGY2 Critical Care Program Director
Henry Ford Hospital
Detroit, Michigan
  View Biography

Breathing Easy: A Guide to Medication Management in Pulmonary Hypertension

2:30 PM to 3:15 PM
Maria R. Guido, Pharm.D., BCPS
Speaker:Maria R. Guido, Pharm.D., BCPS

Specialist, Drug Policy | Clinical Pharmacy Specialist, Pulmonary Hypertension

UC Health | Cincinnati, OH

 

  View Biography

Cookies

This website uses cookies to help ACCP provide you with the best user experience. If you continue to use our services, ACCP will assume that you agree to the use of such cookies. You can find out how to update your settings by referring to ACCP’s Policy on Cookies.